Phytic Acid-Based Ternary Complex Biomimetic Nanomaterial for Tumor Targeting
Summary
The USPTO published patent application US20260108641A1, filed July 25, 2024 (application No. 19487095), disclosing a phytic acid (PA)-based ternary complex biomimetic nanomaterial formed by connecting proteins or polypeptides to PA using metal cations as bridging agents. The invention constructs a novel nanotheranostic probe with high biocompatibility that can reassemble and persistently accumulate at tumor sites, enabling coordination loading of imaging/therapeutic metal ions for long-lasting tumor imaging, treatment, or integrated diagnosis and treatment.
“A phytic acid (PA)-based ternary complex biomimetic nanomaterial consisting of PA, metal ions and a protein/polypeptide is provided, and it is formed by connecting the protein/polypeptide with PA using metal cations as a cation bridge.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108641A1 disclosing a phytic acid-based ternary complex biomimetic nanomaterial. The material is formed by connecting proteins or polypeptides to phytic acid using metal cations as cation bridges, creating a nanotheranostic probe with high biocompatibility that can reassemble and persistently accumulate at tumor sites for imaging and therapeutic applications.
Pharmaceutical, biotechnology, and medical device companies active in nanomaterials, targeted drug delivery, or cancer diagnostics should note this application as it progresses through prosecution. Parties conducting freedom-to-operate assessments or monitoring the competitive landscape in nanotheranostics may find this disclosure relevant.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHYTIC ACID-BASED TERNARY COMPLEX BIOMIMETIC NANOMATERIAL, AND PREPARATION METHOD AND USE THEREOF
Application US20260108641A1 Kind: A1 Apr 23, 2026
Inventors
Yang ZHAO, Dengyi DUAN, Gang HAN, Jing PENG
Abstract
A phytic acid (PA)-based ternary complex biomimetic nanomaterial consisting of PA, metal ions and a protein/polypeptide is provided, and it is formed by connecting the protein/polypeptide with PA using metal cations as a cation bridge. The PA ternary complex having different protein/polypeptide groups is synthesized with various metal ions as bridges. A novel nanotheranostic probe having high biocompatibility is constructed. The probe may be reassembled and gathered persistently at tumor sites, allowing for the coordination loading of imaging/therapeutic metal ions. This enables long-lasting tumor imaging, treatment or integrated diagnosis and treatment, showing promise as a novel biomimetic nanomaterial in the field of biomedicine. In addition, the preparation process of the nanomaterial is simple and easy for industrial production.
CPC Classifications
A61K 51/081 A61K 49/04 A61K 49/10 A61K 49/14 A61K 49/143 A61K 51/082 A61K 51/088 A61K 2121/00 A61K 2123/00
Filing Date
2024-07-25
Application No.
19487095
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.